NFE2L2 and lung carcinoma: Telkoparan-Akillilar et al. have addressed the regulation of the NRF2 signaling pathway, anticancer activity, and the difficulties in developing NRF2-based cancer therapeutic options.16 Novel technologies such as CRISPR/Cas9 was used to disable the NRF2 gene in chemoresistant lung cancer cell.48 The combined action of CRISPR-directed gene editing and chemotherapy increased effectiveness of the anticancer drugs cisplatin, carboplatin, and vinorelbine.